PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Thorax. 2007 July; 62(7): 561–562.
PMCID: PMC2117246

Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?

An estimated 150 000 patients develop a pleural effusion each year in the UK. Establishing the aetiology of pleural effusions can be challenging as they can be associated with over 50 systemic or pulmonary disorders.1 Exudative pleural fluids arise from plasma extravasation and contain proteins and cells from the systemic circulation, as well as those released locally from the pleura. This milieu of cellular products potentially holds vital clues that can unveil the underlying cause of the effusion. Decoding these clues has been a long and slow journey,2 and only in recent years have several disease‐specific pleural fluid markers been incorporated into clinical practice (eg, adenosine deaminase for tuberculous pleuritis3 and brain natriuretic peptide for effusions from cardiac failure).

It is logical that diagnostic clues for mesothelioma, a primary pleural malignancy, would rest within the pleural fluid. The incidence of mesothelioma is rising significantly in the UK and other European countries. Most patients with mesothelioma present with a pleural effusion, and this diagnosis should be considered in all patients with exudative effusions. However, fluid cytology has a notoriously low diagnostic yield, as differentiating mesothelioma cells from benign (or reactive) mesothelial cells is difficult. More invasive procedures such as thoracoscopy for tissue biopsy samples are frequently required.4

Finding a diagnostic marker for mesothelioma is a challenging endeavour.5 This is made difficult by the heterogeneity of mesothelioma, which comprises various histological subtypes (eg, epithelioid, sarcomatoid, desmoplastic) with dissimilar gene expression patterns,6 phenotypes and biological features.4 No unique molecule has been shown to reliably define mesothelioma from benign mesothelium or metastatic carcinomas, even by profiling the expression of tens of thousands of genes on mesothelioma tissues using microarray technology.7

Soluble mesothelin in mesothelioma

The Food and Drug Administration has recently approved the use of soluble mesothelin for disease monitoring in mesothelioma. This followed the findings of Robinson et al8 that blood levels of soluble mesothelin are significantly raised in patients with mesothelioma compared with controls with a wide range of pleuropulmonary diseases. This observation is robust and has been confirmed by other studies.9,10,11 Mesothelin is a 40 kDa glycoprotein predominantly found in normal mesothelial cells in the pleura, peritoneum and pericardium. Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin‐related peptides (SMRP or “soluble mesothelin”) has been found in the serum. It has been suggested that the protein may be a splice variant of the normal mesothelin, with structural variation that alters its binding to cells.12 More recently it has been suggested that SMRP are mesothelin molecules released into the systemic circulation from malignant cells that overexpress mesothelin.13,14

Most (>95%) patients with mesothelioma have a pleural effusion; it would be logical to assess the usefulness of soluble mesothelin in pleural fluid as a diagnostic test for mesothelioma. In this issue of Thorax, Creaney et al15 report that soluble mesothelin is detectable in pleural and peritoneal effusions and its levels are significantly higher (median 7‐fold) in pleural mesothelioma (n = 52) than in effusions of benign pleuritis (n = 84) and non‐mesothelioma malignancies (n = 56) (see page 569). Levels of soluble mesothelin were also higher in ascitic fluid from peritoneal mesothelioma than in benign controls.

Using a cut‐off that yielded 98% specificity, the sensitivity of raised soluble mesothelin in pleural fluid was 67% for all pleural mesothelioma and 77% for epithelioid mesothelioma. The results from the study by Creaney et al15 echoed those from a multicentre study from France which compared mesothelin levels in pleural fluid from patients with mesothelioma, metastatic carcinomas and benign asbestos pleural effusions. Scherpereel et al9 found a similar sensitivity (65%) for pleural fluid mesothelin with a specificity of 84%. To put this in context, soluble mesothelin has a much more favourable sensitivity than other tumour markers adopted in routine clinical practice, including prostate specific antigen (21%),16 carcinoembryonic antigen (11%)17 and cancer antigen (CA)‐125 (57%)18 at similar specificity cut‐off points (94–100%).

In both studies the sensitivity of soluble mesothelin was limited by the lack of reactivity in sarcomatoid tumours9,15 and some of the “mixed” mesotheliomas, presumably ones with a heavy sarcomatoid component. In both studies the sensitivity and specificity were calculated using a cut‐off value determined in the same cohort. The cut‐off values have not been tested in a separate cohort to confirm the sensitivity and specificity.

False positives also occur:5 soluble mesothelin is released in significant quantities by ovarian and pancreatic carcinomas, as well as by a small proportion of lung carcinomas and, in the current series, a patient with lymphoma.15 Immunohistochemistry has revealed mesothelin staining in several types of non‐mesothelioma cancers19 such as tumours of the gastrointestinal tract. It is likely that some of these tumours will shed mesothelin into the blood or serosal fluids. Because of the significantly higher incidence of malignant ascites from ovarian carcinomas, the value of soluble mesothelin in peritoneal fluid as a diagnostic marker for mesothelioma will be lower than in pleural effusions.

Pleural fluid levels of soluble mesothelin were significantly higher than—but strongly correlated to—corresponding serum levels in the study by Creaney et al.15 This would be consistent with the belief that mesothelin is released from pleural mesothelioma cells into the pleural effusion and probably absorbed subsequently into the systemic circulation. As such, pleural fluid levels of soluble mesothelin may be a more sensitive test than serum levels in diagnosing mesothelioma. Measurement of soluble mesothelin levels in both pleural fluid and serum may further increase the sensitivity.

The level of soluble mesothelin, either in the blood or pleural fluid, did not predict survival when adjusted for the histology.8,15 However, it may reflect tumour load as a rapid reduction in mesothelin levels was observed after debulking surgery for peritoneal mesothelioma.10 A biomarker that reflects the tumour response to mesothelioma treatment would be extremely useful, especially in research settings, as radio‐logical parameters are difficult to follow in mesothelioma because of the presence of effusions or prior pleurodesis. These aspects of soluble mesothelin require confirmation in large prospective studies.

Interestingly, soluble mesothelin has made its way into clinical practice as a biomarker when the biology of mesothelin is still relatively unknown. This molecule has a role in mediating cell adhesions, and strategies to antagonise mesothelin have shown promise as innovative treatments for mesothelioma.12 Phase I trials of anti‐mesothelin treatment have been completed and more advanced clinical trials are underway. Targeting mesothelin may also allow the development of novel radiological imaging techniques to “home in” specifically on the mesothelium and mesotheliomas.

How would mesothelin fit into the diagnostic algorithm for exudative effusions?

A definitive and watertight diagnosis of mesothelioma is important for determining treatment regimes (eg, pemetrexed) and securing compensation claims. Soluble mesothelin, with its limitations, cannot replace histocytological diagnosis as the “gold standard”. However, it may offer additional value to the existing diagnostic tests for pleural effusions. It provides a significantly better sensitivity than cytological examination. An increased pleural fluid level of mesothelin, though not diagnostic on its own, would raise a strong suspicion of mesothelioma or metastatic (especially ovarian or pancreatic) carcinomas and would help direct further investigations (eg, thoracoscopy). Indeed, seven patients in the study by Creaney et al15 had a raised mesothelin level in their effusions up to 10 months before the diagnosis was established. A raised soluble mesothelin level may also provide supportive evidence towards a diagnosis of mesothelioma in cases where the histopathology is inconclusive or in patients unsuitable for invasive biopsies.

Measuring the pleural fluid level of soluble mesothelin is convenient as most patients will undergo thoracentesis in the investigation of their effusions. Soluble mesothelin can be assayed in stored effusion samples, which will allow clinicians to retrospectively request the test should the initial investigation of the effusions fail to reveal a diagnosis. The commercially available enzyme‐linked immunoabsorbent assay has been shown to be reliable for measurement of soluble mesothelin.11

Soluble mesothelin is a useful marker for epithelioid mesothelioma but not for other histological variants of mesothelioma. The charge now is to seek an equivalent marker for sarcomatoid mesothelioma to be used in combination with soluble mesothelin, which will vastly enhance its clinical usefulness. Attempts to improve the diagnostic yield by using better antibodies are also underway.12,13

An ideal diagnostic marker with perfect accuracy will never be found. Soluble mesothelin represents a significant step towards the goal of diagnosing the cause of pleural effusions without involving invasive procedures.

Footnotes

Dr Lee is supported by a Wellcome Advanced Fellowship and by project grants from the Medical Research Council (UK), British Lung Foundation and NH&MRC (Australia).

References

1. Light R W, Lee Y C G. Textbook of pleural diseases. London: Arnold Press, 2003
2. Lee Y C G, Davies R J O, Light R W. Diagnosing pleural effusion: moving beyond transudate‐exudate separation. Chest 2007. 131942–943.943 [PubMed]
3. Perez‐Rodriguez E, Jimenez Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med 2000. 6259–266.266 [PubMed]
4. West S D, Lee Y C G. Current management of malignant pleural mesothelioma. Clin Chest Med 2006. 27335–354.354 [PubMed]
5. Scherpereel A, Lee Y C G. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007. 13 (in press)
6. Kettunen E, Nicholson A G, Nagy B. et al L1CAM, INP10, P‐cadherin, tPA and ITGB4 over‐expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 2005. 2617–25.25 [PubMed]
7. Gordon G J. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer 2005. 49(Suppl 1)S99–103.103 [PubMed]
8. Robinson B W S, Creaney J, Lake R. et al Mesothelin‐family proteins and diagnosis of mesothelioma. Lancet 2003. 3621612–1616.1616 [PubMed]
9. Scherpereel A, Grigoriu B, Conti M. et al Soluble mesothelin‐related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006. 1731155–1160.1160 [PubMed]
10. Hassan R, Remaley A T, Sampson M L. et al Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006. 12447–453.453 [PubMed]
11. Beyer H L, Geschwindt R D, Glover C L. et al MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007. 53666–672.672 [PubMed]
12. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004. 103937–3942.3942 [PubMed]
13. Hellstrom I, Raycraft J, Kanan S. et al Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006. 151014–1020.1020 [PubMed]
14. Ho M, Onda M, Wang Q C. et al Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006. 151751
15. Creaney J, Yeoman D, Naumoff L K. et al Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007. 62569–576.576 [PMC free article] [PubMed]
16. Thompson I M, Ankerst D P, Chi C. et al Operating characteristics of prostate‐specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005. 29466–70.70 [PubMed]
17. Goldberg E M, Simunovic L M, Drake S L. et al Comparison of serum CA 19‐9 and CEA levels in a population at high risk for colorectal cancer. Hybridoma 1989. 8569–575.575 [PubMed]
18. Helzlsouer K J, Bush T L, Alberg A J. et al Prospective study of serum CA‐125 levels as markers of ovarian cancer. JAMA 1993. 2691123–1126.1126 [PubMed]
19. Ordonez N G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003. 16192–197.197 [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group